Gene therapy, a promising field using genes as medicine, holds vast potential for treating challenging genetic diseases and cancers that were previously considered untreatable. It involves introducing genetic material into cells using viral vectors as carriers to restore normal cell function.
The growing interest in gene therapy has created a significant demand for viral vectors suitable for clinical trials. This program has established a vector production facility that adheres to good manufacturing practices (cGMP) standards to meet this rising demand for use in human clinical trials. This achievement places New South Wales at the forefront of vector production in Australia, offering economic benefits through intellectual property rights and commercialisation.
This facility leverages our world-class expertise in vector development and enables the initiation of crucial paediatric gene therapy clinical trials for a range of diseases such as cancer, eye, kidney and liver conditions. Additionally, it can produce vectors for the broader New South Wales and Australian research community, promoting the advancement of gene therapy for clinical applications. This transformative initiative has also set the foundation for establishing a large-scale national production capacity with global reach.